Enzene Inc.

Enzene is an integrated global CDMO offering services spanning discovery, development and commercial supply. Its patented Fully Connected Continuous Manufacturing (FCCM) platform, EnzeneX, is validated for commercial biologics supply, delivering significantly increased production yields and reduced costs, with a goal of lowering mAb production costs below $40 per gram by 2025. The company's microbial and mammalian drug substance plants, as well as its sterile fill and finish plant in India, are EU-GMP certified.